TrialThe Journal of infectious diseases2023

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.

Isabel Leroux-Roels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.